迪西塔马韦单抗(Disitamab Vedotin)通过诱导铁死亡(ferroptosis)来激活CD8+ T细胞的抗肿瘤免疫功能,从而治疗HER2阳性乳腺癌。
Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer
Zhao Yingying, Yuan Chenwei, Wu Qiong, Wu Ziping, Peng Jing, Lin Yanping, Lu Jinsong, Yin Wenjin
Journal:JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
IF:14.3
DOI:10.1186/s13046-026-03836-x
PMID:
Published:2026-09-29
research field:分子生物学癌症生物学细胞生物化学
Abstract
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The development of anti-HER2 antibody–drug conjugates (ADCs) has markedly improved outcomes. Disitamab vedotin (RC48) is a novel anti-HER2 ADC that exhibits antitumor activity against both HER2-positive and HER2-low breast cancers, although its molecular mechanism of action remains incompletely understood. Here, we show that RC48 triggers the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis and the subsequent release of damage-associated molecular patterns (DAMPs) that initiate immunogenic cell death (ICD). DAMP emission promotes dendritic cell maturation and increases CD8 + T-cell infiltration and cytotoxicity within the tumor microenvironment. In vivo mouse models confirm the efficacy and safety of RC48 both as a monotherapy and as part of a combination therapy with anti-programmed cell death ligand 1 (PD-L1). Collectively, our findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


